Two well-funded AI medical scribe makers cut staff within days of each other as hospital sales lag

Two of the best-funded companies selling AI note-taking tools to doctors have cut staff within days of each other. Abridge, valued at $5.3 billion last year, confirmed an "organization-wide realignment" on Monday. Heidi, an Australian rival valued at A$1.26 billion in September, is cutting about 18% of its workforce.

Either cut alone would be a routine startup story. Together they say something about one of the most crowded corners of health care AI. Both companies raised large sums recently and both insist they are still growing. Yet both are reshaping their teams around a market where hospitals sign contracts slowly, and where the dominant medical records vendor now sells its own version of the product.

These tools are known as ambient AI scribes. They listen to a doctor's conversation with a patient and draft the visit note, so clinicians spend less time typing into records systems.

What each company says

Abridge has not said how many people lost their jobs or where. In an email to KRON4, the company said it is "realigning from a position of strength" and offering transition packages and outplacement help. Two self-described former employees, one in the Bay Area and one in New York, posted on LinkedIn that they were let go after less than a year.

According to the health IT newsletter HISTalk, Abridge says the goal is a flatter structure and faster product development. The company says it serves more than 300 health systems. It also says it still holds more than half of the roughly $750 million it has raised and will keep hiring in priority areas. Its last major round, in June 2025, raised $300 million led by Andreessen Horowitz.

Heidi has been more candid. The Melbourne company employs more than 600 people, so the cut likely affects over 100 roles. Chief executive Tom Kelly told the Australian Financial Review, as reported by Medical Republic, that Heidi had been "too optimistic" about how quickly large health systems would buy. It had put too many staff into enterprise roles ahead of hospital deals that were slow to arrive.

Kelly told staff the company was not putting investment "into the right teams and markets," according to HTWorld. Medical Republic reported that investors pushed for a more predictable business, and, citing the AFR, that some roles are moving offshore. Two co-founders are also stepping back. Finance chief Waleed Mussa is leaving, and technology chief Yu Liu is moving to an advisory role until March 2027.

The timing stands out. In September Heidi announced a funding package of about A$475 million. That included a US$100 million equity round valuing it at A$1.26 billion and a US$240 million debt facility earmarked for winning customers. Heidi says its product now supports three million patient interactions a week.

The Epic problem

Neither company blamed a competitor. But Medical Republic identified the US as Heidi's main pressure point, because Epic launched its own scribe in February. Epic's records software is already installed at many of the hospitals these startups sell to.

Epic's tool, called AI Charting, drafts visit notes and orders from inside the records system that hospitals already pay for. Epic has not published its price. At launch, trade outlets HIT Consultant and Digital Health Insights both argued it threatens standalone vendors, with both naming Abridge and Nabla. That was analysis, not measured customer loss.

The argument is simple for a hospital finance chief. A separate scribe vendor means a separate contract, a separate security review and separate fees, which HIT Consultant says often cost millions. A built-in option from an existing supplier invites the question of whether the extra contract is worth renewing at all.

The market is also smaller than the valuations might imply. Digital Health Insights, citing Grand View Research, put the AI medical scribe market at roughly $400 million. It also reported that 62% of Epic customers had already rolled out some ambient tool by mid-2025, which leaves fewer new hospitals to sign.

What buyers and investors should watch

The evidence on value is real but modest. A September review of published studies by Rajesh Beri, writing in his own AI newsletter, found the largest study, across five academic medical centers, showed about 16 fewer minutes of documentation per eight-hour day. In one randomized trial of 238 physicians, Microsoft's DAX showed no statistically significant time savings, while Nabla cut note time by 9.5% compared with usual care. These figures come from that single review.

Abridge does have an edge here. Beri's review found it was the only named product in his comparison with a peer-reviewed time-savings result, from a University of Chicago group. Epic has published no outcome data specific to AI Charting. Abridge also works inside Epic's own software rather than against it, Beri notes.

For hospital buyers, the practical takeaway is leverage. Renewals with standalone scribe vendors can now be priced against Epic's bundled option. Beri recommends a head-to-head pilot before signing.

For investors, the cuts are an early test of a wider question. Many AI application companies sell a feature that a large incumbent platform can copy and bundle. Fast revenue growth does not settle that risk. As Kelly reportedly put it, the next investor might not be there even if scribe revenue triples.

Heidi says it will share its revised structure this week. Abridge has not said whether more changes are coming. Watch whether rivals follow with their own cuts, and whether large health systems start dropping standalone scribe contracts in favor of Epic's.